Last reviewed · How we verify
Oil special 107 and MYGLIOL 810
Oil special 107 and MYGLIOL 810 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
At a glance
| Generic name | Oil special 107 and MYGLIOL 810 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oil special 107 and MYGLIOL 810 CI brief — competitive landscape report
- Oil special 107 and MYGLIOL 810 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Oil special 107 and MYGLIOL 810
What is Oil special 107 and MYGLIOL 810?
Oil special 107 and MYGLIOL 810 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Oil special 107 and MYGLIOL 810?
Oil special 107 and MYGLIOL 810 is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
What development phase is Oil special 107 and MYGLIOL 810 in?
Oil special 107 and MYGLIOL 810 is in Phase 1.